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Abstract
Multiple myeloma (MM) is a B cell malignancy characterized by the expansion of clonal plasmablast/plasma cells within the
bone-marrow. It is well established that the bone-marrow microenvironment has a pivotal role in providing critical cytokines
and cell–cell interactions to support the growth and survival of the MM tumor clone. The pathogenesis of MM is, however,
only fragmentarily understood. Detailed genomic analysis reveals a heterogeneous and complex pattern of structural and
numerical chromosomal aberrations. In this review we will discuss some of the recent results on the functional role and
potential clinical use of the IGF-1R, one of the major mediators of growth and survival for MM. We will also describe some of
our results on epigenetic gene silencing in MM, as it may indeed constitute a novel basis for the understanding of tumor
initiation and maintenance in MM and thus may change the current view on treatment strategies for MM.
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Introduction
Among the hallmarks of multiple myeloma (MM) is
the characteristic accumulation of malignant cells
with plasmablast/plasma cell phenotype preferably
in the bone-marrow compartment. In many instances
MM is preceded by monoclonal gammopathy of
undetermined signiﬁcance (MGUS), a pre-malignant
state without clinical symptoms of malignancy (1).
Unlike normal plasma cells, MM cells proliferate,
although at a low rate (typically less than 1% of the
cells display DNA synthesis at early disease stages),
and have the capacity of prolonged survival and
extended self-renewal. However, the mechanisms
underlying such deregulation of the proliferation
and differentiation processes as well as the apoptotic
machinery in MM cells are only fragmentarily under-
stood. Characteristic of the complex pathogenesis of
MM is the genetic instability, as reﬂected by an
extensive clonal variation between and within the
tumor clones as displayed in patients and transgenic
mouse tumor models (2-6). So far, a common pattern
of structural and numeric chromosomal alterations
has not been found, but genetic subgroups have
indeed been identiﬁed (3). Although these have
been used for sub-classiﬁcation of MM, accumulating
evidence shows that these identiﬁed genetic altera-
tions are likely insufﬁcient for malignant transforma-
tion (7). There is therefore still an urgent need to
identify new genetic lesions, functional as common
drivers of proliferation and stemness, markers for
tumor progression, and, most importantly, rational
biological targets for treatment in order to improve
the outcome for patients with MM.
Highlighting the importance of the microenviron-
ment for the initiation and maintenance of MM, the
multi-faceted roles of insulin-like growth factor
(IGF)-1 is now emerging, not only as a locally pro-
duced survival and growth factor, but also as a protein
with novel functions, i.e. regulating gene expression,
directly by shuttling to the nucleus (8), or indirectly,
altering gene activation by histone modiﬁcations (9).
Taken together, these novel ﬁndings further validate
the beneﬁts of targeting the IGF-1R in designed
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into account, for therapeutic use in MM. By changing
the focus from chromosomal aberrations to the use of
an integrative genomics strategy, taking into account
genetic as well as epigenetic alterations underlying a
global RNA expression pattern in MM, we have
recently contributed to the understanding of tumor
initiation and maintenance of self-renewal in this
plasma cell tumor (10).
The role of genetic alterations in MM
Genetic aberrations in MM display a heterogeneous
pattern with large intra- and interclonal variability.
Most prominent of the genetic lesions are transloca-
tions to the Ig locus of ﬁve selected partner genes:
11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (ﬁbroblast
growth factor receptor 3 (FGFR3) and multiple mye-
loma SET domain (MMSET)), 16q23 (c-maf), and
20q11 (mafB) (11). MM is often, if not always,
preceded by MGUS. However, not all cases of
MGUS develop into overt MM. The genetic events
mediating the transformation from MGUS to MM
and the de novo transformation of MM are, however,
largely unknown. Although IgH translocations are
sometimes referred to as primary genetic events in
MM transformation, they are also present in about
50% of MGUS (12,13). Therefore, these events are
considered insufﬁcient for malignant transformation.
Cyclin D1 has been found to be uniformly and aber-
rantly activated by all these translocations in MM and
has therefore been suggested to be a common down-
stream denominator of the transformation process.
This ﬁnding, together with the fact that cyclin D is not
expressed in normal hematopoietic cells and normal
plasma cells, points to the possibility that there may be
therapeutic windows for all molecular subtypes of
MM by targeting this pathway (11). Although the
prevalence of IgH translocations is increasing with
disease stage of MM and present in >90% of human
MM cell lines, their role in transformation of MM
has been questioned by the fact that they are insuf-
ﬁcient for recapitulating the process of initiating
MM in transgenic mouse models (7). However, by
reﬁning the molecular classiﬁcation based on the
presence of IgH translocations and cyclin D gene
expression, seven subclasses of MM are distinguish-
able (14,15). Considerable controversy, however, still
exists concerning the clinical value of genetic lesions
including IgH translocations as independent prognos-
tic markers or valid as possible therapeutic targets
(16,17). Secondary genetic events are numerous in
MM, e.g. activating mutations of K- or N-Ras (18),
disruption of the Rb pathway by inactivation/biallelic
loss of Rb or p18INK (19,20), and PTEN mutations
(21). The p53 status in subsets of MM is gaining new
interest in molecular diagnostics, as p53 mutations
were recently found to be tightly associated with
monoallelic loss of 17p in poor-prognosis patients
(22). Although aberrant expression of c-myc has usu-
ally been considered a late event in MM pathogenesis
(23), c-myc was recently found to be activated during
the transition from MGUS to MM in two-thirds of
myeloma (24). This suggests that activation of c-myc
may indeed occur early in the development of MM.
Most likely multiple mechanisms, IgH translocations
excluded, are involved in activation of c-myc (23).
Pointing to one of these in the study by Chng et al.
(24), the myc-induced gene signature corroborated,
with few exceptions, with the presence of ras muta-
tions in MM. In line with this regained importance of
myc in MM pathogenesis, the interferon regulatory
factor (IRF) 4, a direct target of c-myc activation, was
recently identiﬁed among other oncogenic candidates
to be indispensable for MM tumor growth, although
sparsely involved in genetic alterations and transloca-
tions (25). Interestingly, mouse models displaying
plasma cell tumors have recently been generated by
conditional c-myc activation in GC B cells through the
use of the physiological process of somatic hypermu-
tation (SHM) (4). These alterations largely differ
from the genetic alterations of myc, mainly transloca-
tions emerging in the classical mineral-oil-induced
plasmacytoma initially described by Potter et al.
(26). In contrast to this model, the conditional acti-
vation of myc in GC cells undergoing SHM in the
Vk*myc model gave rise to tumors of postgerminal
center origin (4). These tumors were indeed found to
have biological and clinical features resembling
human MM. The unique proﬁle of myc-activated
genes in MM, as compared to MGUS, suggests
that myc during the transformation process may still
represent a secondary genetic lesion in cells already
hit by a primary event, i.e. IgH translocations or cyclin
D1 activation (4).
Perhaps more powerful techniques, including high-
throughput RNA-based proﬁling, taking into account
copy number alterations, translocations, and epige-
netic silencing by histone and DNA-based modiﬁca-
tions, should be more useful in revealing crucial
genetic transforming events, markers for poor prog-
nosis, and common targets for therapeutic use.
Recently, two large studies using these techniques
report two independent sets of genes for the identi-
ﬁcation of poor-risk patient populations (27,28).
Also, the ﬁrst study using massively parallel sequenc-
ing of 38 MM genomes could conﬁrm previously
described mutations in MM, but it also identiﬁed
novel genetic lesions, i.e. BRAF mutations, in a small
fraction of MM patients that may indeed have
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connect expression proﬁles to speciﬁc signaling path-
ways have led to the discovery of activating mutations
in the NF-kB pathway that certainly will prove impor-
tant for new treatment strategies (30,31). Adding to
this notion, the possibility of gaining knowledge of the
mechanisms of gene activation in the tumor clone, i.e.
by analysis of histone modiﬁcations of chromatin
regulating gene silencing and constituting a basis
for self-renewal and proliferation, was recently sug-
gested by us (10). Taken together these ﬁndings may
indeed prove gene proﬁles to be useful for prognostic
purposes, for deﬁning the nature of the tumor-
initiating clone in MM, and for ﬁnding novel treat-
ment strategies.
The role of the microenvironment in
supporting growth and survival of MM cells
It has become increasingly evident that the design of
selective targeting drugs for tumor therapy should
take into account also the survival beneﬁts of the
tumor–stroma interactions. It is an established fact
that cell–cell contacts, cell–extracellular matrix inter-
actions, and cytokines produced by the bone-marrow
stromal cells are all important factors regulating
growth and survival of MM cells (5,32–34). Several
of these cytokines have been demonstrated to pro-
mote the growth, survival, and apoptosis of MM cells.
Among these, IL-6 and IGF-1 were demonstrated by
us and others to be major paracrine and autocrine
growth and survival factors in MM cells in vitro and
in vivo (34–38). It has also become increasingly clear
that soluble factors may not only directly stimulate the
expansion of the tumor clone, e.g. BAFF, APRIL,
IL-10, and IL-15 (39), but in some cases (bFGF,
VEGF) they may also indirectly contribute to tumor
growth by triggering angiogenesis and/or production
of growth-promoting factors by the surrounding nor-
mal bone-marrow cells, i.e. osteoblasts, ﬁbroblasts,
and endothelial cells (40,41). The prime focus of our
research interest has in recent years been the IGF-1, a
cytokine not only providing survival and growth
beneﬁts to the malignant plasma cells by autocrine
stimulation and by paracrine signaling from the sur-
rounding tumor stroma (38), but also by its function
as a chemoattractant of MM cells guiding the tumor
cells to the preferable site of growth in the bone-
marrow compartment (42).
The complex IGF system consists of three ligands,
IGF-1, insulin, and IGF-2, at least ﬁve cell-
membrane receptors, IGF-1 receptor (IGF-1R), insu-
lin receptor (IR), splice variants IR-A and IR-B, and,
without obvious transmembrane signaling activity,
the IGF-2 receptor (IGF-2R) (Figure 1). The
extracellular a-subunit contains the ligand-binding
domain of the IGF-1R, with afﬁnity for IGF-1 and
IGF-2 (43). Ligand binding induces a conformational
shift in the covalently bound b-subunit now promot-
ing attraction of adaptor proteins IRS, SHC, and
Grb2 to the phosphorylated sites of the receptor. In
turn, the SH2 domain containing proteins may trans-
duce the signal to downstream activation pathways,
including the extracellular signal regulated kinase
(ERK) and protein kinase B (PKB/AKT), for prolif-
eration and survival control. The formation of hybrid
IGF-1R IGF-1R:IR IGF-2R IR IR-A
IGF-1 IGF-2 Insulin
Figure 1. The most prominent ligand-receptor interactions with superior afﬁnity over other ligands, i.e. IGF-1 to the IGF-1R and hybrids with
either IR-A or IR-B, IGF-2 binds with high afﬁnity IGF-1R, IR-A, and heterodimers with this isoform, while insulin displays high afﬁnity for
the IR and splice variants IR-A and IR-B only.
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contribute to tumor growth as shown in several
in vitro tumor models, including breast carcinoma
cell lines (44). As the IR exists in two isoforms
(IR-A and IR-B), the formation of receptor hybrids
hybrid-R with either IR-A or IR-B largely affects the
outcome in signaling and biological consequences
(45). Hybrid-Rs containing IR-A are activated by
IGF-1, IGF-2, and insulin, while the IGF-1R–IR-B
hybrid-Rs preferably bind IGF-1 with high afﬁnity
over IGF-2, and insulin (45) (Figure 1).
Adding to this complexity is the tight control of
bioavailability of the IGF-1 by six high-afﬁnity IGF
binding proteins increasing the ligand half-life. In the
light of this knowledge, it was perhaps not an unex-
pected ﬁnding that the mere presence of IGF-1 in
serum, or the level of IGF-1R on the surface of tumor
cells, has not been found to be a useful biomarker for
tumor incidence or progression (46–48). Despite
ubiquitous expression of the IGF-1R in cell types
originating both from the epithelial and mesenchymal
compartment, reports on the modest use of this
receptor in the control of normal cell growth in the
adult individual indicate the use of this receptor as an
attractive drug target amenable for tumor therapy.
Indicating the importance of the IGF-1R in oncogen-
esis in general, the receptor seems indispensable for
transformation (49), and its overexpression in murine
models may even increase the incidence of tumor
formation (50).
A pivotal role of IGF-1R in the pathogenesis of MM
was originally reported by us (34) and conﬁrmed by
others (37,51). Our previous studies have shown that
IGFs and IGF-1R signaling play critical roles in
stimulation of proliferation, survival, and drug-
resistance of MM (34,52). IGF-1R-antagonistic anti-
bodies (aIR3) interfering with the IGF-1 autocrine
loop or with the IGF-1 axis were later shown to have
comparable effects in profoundly suppressing serum-
induced survival and potentiate apoptosis induced by
glucocorticoids and death receptors, i.e. Fas, in MM
cells (52,53,21,54). In a recent publication, the role of
IGF-1 as a mediator of survival was clariﬁed by
linking the inhibition of apoptosis to the silencing
of important effector genes (9). One of the genes
signiﬁcantly and consistently down-regulated by
IGF-1 stimulation in human and murine MM cells
is the Bim (Bcl2like11) gene, a member of the
BH3-only group of the Bcl-2 protein family, and a
mediator of apoptosis in pathways utilizing the
mitochondrial pathway. Functional studies proved
the importance of Bim in drug-induced apoptosis
of MM. The silencing of Bim by RNAi strategies
rendered MM cell lines in vitro refractory to
bortezomib, melphalan, and histone deacetylation
(HDAC) inhibitors. Analysis of histone modiﬁcations
at the Bim promoter, and its upstream transcriptional
activator, revealed that IGF-1 treatment of MM
resulted in an increase of repressive histone methyl-
ation marks (H3K9me2) and thus reduced transcrip-
tion of Bim (9). This clearly establishes a novel role
for IGF-1 in regulating gene expression by epigenetic
silencing of target genes in MM.
In line with this newly ascribed function, the
IGF-1R recently also joined the group of transmem-
brane receptors, among these the EGFR, that
may undergo translocation to the nucleus (55).
Previous publications even suggest nuclear EGFR
to be a prognostic indicator for poor clinical
outcome and a mediator of aggressiveness of tumor
cells (56). Shuttling of the IGF-1R to the nucleus
and subsequent chromatin binding is a ligand-
dependent process requiring tyrosine kinase activity
and sumoylation of the IGF-1R (8,57). Likely, the
I G F - 1a sw e l la sI G F - 2b i n d i n gt ot h eI G F - 1 Rm a y
induce intracellular transport of the receptor. The
biological role of nuclear IGF-1R is essentially
unknown, but it seems to be associated to pro-
liferative capacity rather than to expression levels
per se. Interestingly, the nuclear IGF-1R was also
shown to be co-localized to RNA polymerase II on
chromatin. Nuclear IGF-1R may be detected in
proliferative benign epithelial cells, in solid tumors
of breast, lung, and prostate, and also in MM
(55,57). Detailed analysis of the contribution of
the nuclear IGF-1R to the activated gene proﬁle
of IGF-1-induced signaling will certainly prove to
be important.
IGF-1R signaling has been established to mediate
survival in authenticated MM cell lines (5) and
CD138+ primary MM cells. Its importance has
also been validated in vivo in the syngeneic mouse
models 5T3MM and 5T2MM, well representative
for human MM (58). This model originated from
spontaneously arising murine MM in C57BL/KaL-
w R i jm i c ea n dm a yb em a i n t a i n e db ys e r i a lt r a n s -
plantation in syngeneic mice (59). The 5TMM
tumor-bearing mice have the advantage of being
immunocompetent. The 5TMM tumor also closely
resembles the human MM with respect to genetic
alterations, tumor location to the bone-
marrow, induction of angiogenesis at the tumor
site, and the presence of osteolytic lesions (60).
Proving the importance of studying the beneﬁts of
survival factors in MM in a syngeneic environment,
IGF-1 was in this model found to induce VEGF
production and angiogenesis and was certainly pro-
ving important for tumor growth. Thus, such a
tumor environment where IGF-1 may directly and
indirectly stimulate tumor expansion seems optimal
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antagonists to the IGF-1R signal in MM (61).
Clinical implications of targeting the IGF-1R in
MM cells in vitro and in the 5TMM model
in vivo
A few selective inhibitors to the IGF-1R (antagonistic
antibodies) or its kinase activation domain (small
synthetic RTK inhibitors) have been described,
some of these tested also in early clinical trials for
solid tumors and MM (62,63). The development of
drugs for selective targeting the IGF-1R was for long
severely hampered by the lack of unique domains in
the kinase activation domain of the IGF-1R (84%
homology between the IGF-1R and insulin R) and the
redundancy of the ligands emitting growth signals as
previously described.
Our publications, describing studies with the small
molecular inhibitor of the cyclolignan family picropo-
dophyllin (PPP) in vitro, showed that selective inhibi-
tion of the IGF/IGF-1R pathway by this drug can be
achieved with a favorable therapeutic window in MM
cell lines and primary cells (61,64,65). Importantly,
inhibition of the IGF-1RTK with PPP was originally
designed to be non-competitive with ATP, suggesting
interference with the IGF-1R at the substrate level
(66). Most importantly the PPP did not show an
inhibitory activity of the insulin receptor (IR) even at
submicromolar concentrations as shown in in vitro and
in vivo kinase assays (64–66). The investigations of the
molecular mechanisms revealed that the inhibition of
the IGF-1R by PPP was associated with growth arrest,
caspase-dependent and -independent apoptosis in
human MM cells, and a reduced expression of anti-
apoptotic genes including Mcl-1. However, not until
proving its potential in a therapeutic setting could the
IGF-1R be considered a potential therapeutic target in
MM. Indeed, a successful eradication of the tumor
clone by PPP in the therapeutic setting of the 5TMM
in vivo model (61,64,65) set the stage for the use of
inhibition of the IGF-1R in MM therapy. In 5T2MM
mice, treatment with PPP also had favorable effects on
the osteolyticprocess. The numberof osteolytic lesions
was almost completely blocked as a result of PPP
treatment. Importantly, the non-toxic effect of long-
term treatment in the mouse model was encouraging,
with no cytotoxic effects or elevated serum glucose
levels (61). An oral IGF-1R inhibitor (AXL-1717) of
cyclolignan is currently in phase I/II in subjects with
advanced cancer (www.axelar.se).
Results from preclinical studies using other strate-
gies inhibiting the IGF-1/IGF-1R now show that
some of the efforts to uniquely antagonize the receptor
at various levels of its signaling pathway have been
successful (63). Several of the humanized IGF-1R
antibodies and small receptor tyrosine kinase (RTK)
inhibitors have been subjected to investigations in
MM in in vitro studies, preclinical mouse models of
MM, and in clinical trials (51,67,68). So far, the
results from the ﬁrst clinical studies using antagonistic
antibodies have unfortunately not lived up to the high
expectations based on the results from the preclinical
studies. Taking into consideration the severe cyto-
toxic side effects reported for antagonistic antibodies
in phase III trials, small molecule IGF-1RTK inhibi-
tors may be preferable to antagonistic antibodies for
clinical use (63,69).
In our preclinical setting for PPP, using the in vivo
MM mouse model 5TMM, the tumor in the treated
mice eventually relapsed (61). The mechanisms
behind the development of refractory tumors are
currently under investigation. The important study
by Hashemi et al. (70) may shed some light on
underlying mechanisms leading to acquired insensi-
tivity to PPP. The genetic alterations induced as a
result of PPP treatment in cultured solid tumor cells
in vitro are numerous. In a few cases the altered genes
were shown and validated by siRNA experiments to
be connected with IGF-1R function, i.e. SOCS3,
BCL2, and MAPK. Importantly, only a reversible
resistance developed in the presence of PPP, even
after long-term cultivation of both solid tumors and
MM in vitro (71) (Jernberg-Wiklund, unpublished
observations). The reversible resistance did not
include genetic alterations, e.g. ampliﬁcations of
several common genes coding for resistance to
drugs (70). Importantly, although not supported by
the in vitro ﬁndings with respect to drug-induced
resistance, the development of drug-resistant clones
in the in vivo model should not be unexpected. The
complex network of IGF-1R signaling is likely to
create feedback signals which may call for combina-
torial designs for improved treatment. Efﬁcient block-
ade of the IGF-1R was previously suggested to induce
a compensatory response in vivo, i.e. leading to an up-
regulation of IGF-1 in serum (46). A recent example
of compensatory signals from the complex IGF net-
work is the IGF-2 ligand binding and signaling via
insulin receptors (IR), contributing to the intrinsic
resistance to anti-IGF-1R antibody treatment in
mouse models of pancreatic tumors (72). However,
using the small synthetic IGF-1R inhibitor PPP we
could show that excess amounts of IGF-2 or insulin
did not overcome the growth inhibitory effects in vitro
(64). Considering the low levels of circulating
IGF-2 in murine serum, a possible feedback signaling
from the IGF-2 via IR receptors in vivo should not be
an expected complication in this model. So far,
encouraging data and absence of severe side effects
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AXL-1717 (73) indicate that feedback mechanisms
as reported by Ulanet et al. (72) might be of less
importance using small synthetic RTK inhibitors.
To counteract the problem of acquired drug resis-
tance in vivo, our group and others have embarked on
the development of combinatorial therapies for MM.
We have focused predominantly on pairing promising
novel anti-tumor agents with agents conventionally
used in MM management. So far, one of the most
successful achievements of apoptosis sensitization was
found by combining IGF-1R or IGF-1R downstream
components, i.e. mTOR inhibitors, with glucocorti-
coids (74). The selective inhibitor of mTOR, rapa-
mycin, exhibiting only cytostatic effects when used as
a single agent in MM models in vitro, mediated a
signiﬁcant potentiation of dexamethasone-induced
apoptosis and suppressed constitutive, serum-,
IGF-1-, and IL-6-induced survival in MM cell lines,
in puriﬁed cells from MM patients (74). Our studies
and those of others on the molecular mechanisms
underlying the observed sensitization to apoptosis
revealed an inhibition of both mTOR- and MEK/
ERK-mediated phosphorylation of the kinase p70
S6K
at required sites for activation, as well as down-
regulation of the cell cycle-regulated proteins cyclin
D2 and D3 (74,75). These studies provide a proof-of-
principle that abrogating parallel survival factor path-
ways from the IGF-1R by use of rapamycin will render
cells susceptible to drug-induced apoptosis, especially
if the underlying mechanism of this combination is
that the drug and inhibitor co-operate by blocking
all activations sites on a common target protein,
the p70
S6K.
This approach points to the possibility that combi-
nations of multiple investigational agents with drugs
intervening with the IGF-1R pathway should be use-
ful in MM. Several preclinical studies support the use
of IGF-1/IGF-1R inhibitors in combination with
other drug strategies. In MM the use of humanized
anti-IGF-1R antibody IMC-A12 (ImClone) has been
shown to act in synergy with mTOR inhibitors, bor-
tezomib and melphalan, in MM models in vitro and
in vivo (68,76). Enhanced effects have also been
reported by use of ATP competitive IGF-1RTK
inhibitors (Novartis; AEW541, ADW742) in combi-
nation with dexamethasone, lenalidomide, and bor-
tezomib (46,77). The combination of mTOR
inhibitors and IGF-1R inhibitors is currently under
investigation in clinical studies (63).
In a recent study by our group the use of synergistic
drug combinations with PPP has been thoroughly
investigated by using high-throughput screening
(HTS) of drug libraries. Several potent compounds
have been identiﬁed, including dexamethasone,
rapamycin, and p38 inhibitors (64). Among these,
enhanced effects on apoptosis enhancement, cell
cycle arrest, and reduced tumor load in the 5TMM
model in vivo were achieved by combining a novel
HDAC inhibitor, LBH589 (panobinostat), with the
IGF-1R inhibitor PPP (78). The mechanisms under-
lying the synergy of this combination are currently
under investigation.
The role of epigenetic gene regulation by the
Polycomb group proteins (PcG) in MM
Although MM cells phenotypically closely represent
postgerminal center plasmablasts/mature plasma
cells, the precise nature of the target cell of transform-
ing mutations in MM is still unknown, as is the
question of the existence and characteristics of
tumor-initiating cells in MM possibly harboring
self-renewal capacity.
In our aim to dissect the nature of the tumor-
initiating capacity in MM, we performed an integra-
tive genomics approach based on the differences in
gene expression between non-malignant and malig-
nant plasma cells (Figure 2). By using this approach,
we could deﬁne a silenced proﬁle consisting of the top
10% most underexpressed genes in MM patients as
compared to normal non-malignant plasma cells from
bone-marrow and tonsillar tissue (79,80). The
silenced genes had a common denominator in that
they were histone H3 tri-methylated at lysine
27 (H3K27me3) and targeted by the Polycomb
repressive complex 2 (PRC2) as previously deﬁned
by Bracken et al. (81). Interestingly, the underex-
pressed gene proﬁle in MM showed a signiﬁcant
overlap to the well-described literature-based concept
of H3K27me3 and EZH2 target genes linked to the
self-renewal capacity of stem cells (82,83). Indicating
the clinical relevance of this ﬁnding, the suppression
of this gene proﬁle was more pronounced in the
advanced stages (ISS stage III as compared to stages
II and I) of MM progression (Figure 2) (10).
The Polycomb repressive complexes 1 and
2 (PRC1 and PRC2) are multiprotein Polycomb
group (PcG) complexes, among which the PRC2 is
involved in the initiation of gene repression (84). The
silencing of genes marked by the PcG proteins is an
established part of the epigenetic memory during
embryogenesis repressing lineage-speciﬁc develop-
mental genes (85,86). The core PRC2 complex is
formed by the suppressor of zeste 12 homolog
(Drosophila) (SUZ12), the embryonic ectoderm
development (EED), the RbAp46/48 (also known
as RBBP7/4), and the enhancer of zeste homologs
1 and 2 (Drosophila) (EZH1/EZH2)—the catalytic
subunits harboring the histone methyltransferase
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(H3K27me3) (84). Interestingly, to increase plasticity
of the chromatin structure, tri-methylation of H3K27
may be part of a bivalent nucleosome mark occurring
together with chromatin marks permissive for tran-
scription, such as methylation of lysine 4 (H3K4me)
(87). After the removal of the silencing H3K27me3
mark individual genes are considered ready for acti-
vation, allowing cells to differentiate to their allocated
destination.
Our results are in agreement with several recent
genome-wide studies implicating Polycomb-mediated
gene silencing in the development of malignancy in
solid tumors (83,88). In multiple types of lymphoma,
breast and prostate cancer, the aberrant expression of
EZH2 is also indicative of poor prognosis and meta-
static tumor (85,89). Also, in MM the overexpression
of EZH2 and other PcG proteins has been conﬁrmed
(10). Several possibilities exist to explain the constitu-
tive expression of EZH2 in MM, including the aber-
rant expression of c-myc as mentioned previously (24).
Thusitispossiblethattumorinitiationandprogression
in MM is not only driven by genetic alterations butalso
by epigenetic events that confer stemness to a
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172 H. Jernberg-Wiklund & K. Nilssonproliferating cell clone devoid of terminal differentia-
tion capacity. Our ﬁndings were recently supported by
a report demonstrating another core constituent of the
Polycomb-repressive complex 1, the Bmi-1, to be
essential for the maintenance of the transformed phe-
notype of myeloma cells both in vitro and in vivo (90).
In line with our ﬁndings it is certainly possible that
Bmi-1 of the PRC1 maintains silencing originally
initiated by the PRC2 complex.
Because primary bone-marrow MM cells have a
very low clonogenic capacity in agarose in vitro, and a
low tumor-forming potential in nude mice, the expan-
sion of MM clones in vivo has been suggested to
depend on a small population of tumor cells with
self-renewal capacity, ‘MM tumor stem cells’ (91).
Matsui et al. (92) showed that only CD138- MM cells
had the capacity of forming tumors in NOD/SCID
mice in vivo, while the bulk of inoculated CD138+
MM cells did not have this capacity. Recently, the
view that CD138- MM cells represented a small
population of ‘MM tumor stem cells’ has been ques-
tioned. Using the in vivo model of 5TMM, Van
Valckenborgh et al. (93) have clearly demonstrated
that both CD138+ and CD138- MM populations
indeed have similar clonogenic capacity and are
tumor-initiating in vivo (93). Interestingly, the
CD138- MM cells were, however, less proliferative
and displayed gene expression corroborating the idea
of a less mature phenotype than the CD138+ MM
cells. The identiﬁcation of the Polycomb-silenced
gene proﬁle in MM patient samples and cell lines
now also implies that this signature is a general feature
shared by a large proportion of the MM cells rather
than conﬁned to a small subpopulation of ‘MM tumor
stem cells’. Importantly, these ﬁndings may call for a
novel concept of tumor stemness and proliferative
capacity in MM.
An emerging question is if targeting the common
denominator for the observed gene silencing can be
used in the treatment of MM, and, if so, whether this
may have consequences as inhibited cell growth
in vitro and in vivo. Although Polycomb target genes
silenced by EZH2 seem more prone to be perma-
nently silenced by DNA methylation, possibly as a
consequence of direct recruitment of DNA methyl-
transferases DNMT1 and 3 to the PcG, recent studies
in prostate cancer suggest that EZH2-mediated his-
tone methylation and DNA methylation may indeed
occur side by side in gene silencing (94,95). Thus
epigenetic gene silencing may in fact be an attractive
drug target due to the fact it can be reverted and in
relevant cases combined with DNA demethylating
drugs, i.e. 5-azacytidine. Initially in the paper by
Kalushkova et al. (10) two chemical inhibitors, the
global histone methylation inhibitor 3-deazanepla
nocin (DZNep) and the histone deacetylase inhibitor
LBH589, were used to show proof-of-principle that
we may indeed successfully reactivate selected genes
carrying the silencing H3K27me3 mark. DZNep and
LBH589 (panobinostat) both reactivated the expres-
sion of selected genes repressed by H3K27me3,
depleted cells from the PRC2 component EZH2,
and induced apoptosis in human MM cell lines
(Figure 3).
In the 5T33MM in vivo model for MM, treatment
with LBH589 thus resulted in up-regulation of genes
in the signature, reduced tumor load, and increased
overall survival (Figure 3). The drugs used for proof-
of-concept may certainly have effects other than tar-
geting EZH2. However, no toxic side effects on
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IGF-1R signaling and epigenetic silencing in MM 173normal blood cells and ﬁbroblasts were monitored at
concentrations inducing apoptosis in MM in vitro
(10). Certainly, more drugs selectively targeting the
components of the PRC2 and PRC1 complex are
needed to unravel the therapeutic potential of reacti-
vating the silenced gene signature in MM.
Concluding remarks
A critical link between IGF-1R signaling and trans-
formation makes this receptor an excellent target for
inhibition of survival circuits in human tumors includ-
ing MM. Adding to our original ﬁnding that IGF-1 is
an important paracrine and autocrine growth and
survival factor, recent reports suggest that IGF-1
may also regulate gene expression via epigenetic
events and via nuclear transportation (8,9,38). Exten-
sive preclinical studies have proved the beneﬁts of
small molecular compounds with selective activity to
the IGF-1R (51,61,64,65), now in clinical trials with
encouraging results so far (73).
In the design of novel drugs for MM, the current
view on the presence of a small population of tumor-
initiating cells uniquely harboring self-renewal capac-
ity and decreased sensitivity or resistance to drugs
should also be challenged. Although the CD138- MM
cells might exhibit less proliferative potential, these
cells apparently do not constitute the entire popula-
tion of ‘MM tumor stem cells’. As proven by recent
ﬁndings (93), also the CD138+ MM tumorcells share
a similar capacity for clonogenic growth and tumor
initiation in vivo. In line with this, we recently pub-
lished an integrative genomic analysis, where tumor
stemness and maintenance of proliferative capacity
may be deﬁned by a Polycomb-silenced gene proﬁle
in MM patient samples and cell lines (10). This
proﬁle is likely a general feature shared by a large
proportion of MM cells rather than restricted to a
small population of ‘MM tumor stem cells’. The
target cell and the initial genetic events for transfor-
mation being unknown in MM, the mechanisms
underlying the acquired Polycomb gene repression
signature in late stages of plasma cell differentiation
remain to be clariﬁed.
Declaration of interest: The authors report no
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